Trials / Active Not Recruiting
Active Not RecruitingNCT04146051
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Cartesian Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Descartes-08 | Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA |
Timeline
- Start date
- 2019-12-04
- Primary completion
- 2025-07-31
- Completion
- 2026-03-31
- First posted
- 2019-10-31
- Last updated
- 2025-05-28
Locations
15 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04146051. Inclusion in this directory is not an endorsement.